Alex Azar, President Donald Trumpâ€™s nominee to head the Department of Health and Human Services, defended himself Tuesday against Democrats who asserted his ties to the pharmaceutical industry would make him less likely to take strong action to lower drug prices.
Mr. Azar said in a hearing before the Senate Finance Committee that his past position as president of an Eli Lilly & Co. affiliate gives him a unique advantage in tackling drug costs.
... To Read the Full Story Subscribe Sign In